Highest-materiality recent filing
Janux Q1 2026 net loss $24.4M; cash $956.4M; discontinues JANX008, initiates JANX014
Net loss of $24.4M for Q1 2026 vs $23.5M YoY; cash and investments at $956.4M.
Janux reports FY2025 net loss $113.6M; cash $966.6M; BMS collaboration with $50M upfront
Cash and short-term investments $966.6M at Dec 31, 2025, down from $1.03B a year ago.
Janux licenses tumor-activated therapeutic to BMS for solid tumors; up to $800M milestones
Upfront $15M and near-term milestone $35M; total milestones up to ~$800M.
Janux Q1 net loss $23.5M; initiates JANX007 Phase 1b expansion in mCRPC
Initiated Phase 1b expansion with JANX007 in taxane-naïve mCRPC; updated median rPFS 7.5 months (n=16).
Janux Therapeutics reports FY2024 net loss $69M, cash $1.03B, positive JANX007 data
Cash and short-term investments $1.03B at year-end 2024, up from $344M in 2023, largely from $402.5M December offering.
Janux Therapeutics prices $350M public offering of common stock and pre-funded warrants
Priced 5,317,460 shares at $63.00/share and pre-funded warrants for 238,095 shares at $62.999
Janux reports positive interim JANX007 data; selects doses for Phase 1b expansion in mCRPC
100% of 16 patients achieved PSA50 declines; 63% PSA90; 31% PSA99 declines.
Janux Q2 2024 net loss $6.0M; cash $646.3M; receives $7.5M Merck milestone
Net loss of $6.0M vs $17.5M in Q2 2023; improvement driven by $7.5M milestone payment from Merck.
Jay Lichter, Ph.D. resigned from the board effective July 19, not due to any disagreement.
Janux Therapeutics Q1 2024: Cash $651.8M; net loss $14.8M; trials ongoing
Cash and short-term investments $651.8M as of March 31, 2024, up from $344.0M at Dec 31, 2023.
Janux reports $344M year-end cash; Q4 net loss $11.8M; positive Phase 1 JANX007/JANX008 data
Year-end cash & investments $344M; net loss $58.3M for FY 2023 vs $63.1M in 2022.
Janux Therapeutics prices $296.5M public offering of common stock and pre-funded warrants
Pricing: 4,440,851 shares at $46.50/share and pre-funded warrants to purchase 1,935,483 shares at $46.499.
In connection with Dr. Lichter’s resignation, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), Ron Barrett, Ph.D. was appointed as Chair of the Board.
On July 19, 2024, Jay Lichter, Ph.D. resigned as a member of the Board of Directors (the “Board”) of Janux Therapeutics, Inc. (the “Company”), including his chairmanship of the Board, effective as of such date.
On July 19, 2024, the Board, upon the recommendation of the Nominating and Governance Committee, appointed (i) Natasha Hernday as a Class II director of the Company, with a term of office expiring at the Company’s 2026 annual meeting of stockholders, or until her earlier death, resignation or removal.
and (ii) Eric Dobmeier as a Class III director of the Company, with a term of office expiring at the Company’s 2027 annual meeting of stockholders, or until his earlier death, resignation or removal.
Max materiality 0.90 · Median 0.65 · Most common event earnings